ArticleAnnals of surgical oncology2025
Increasing Rates but Persistent Variability of Immediate Breast Reconstruction: Real-Time Data from a Population-Based Study (2012-2022).
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPreserving the breast contour after mastectomy is proven to be beneficial for the quality of life of a large group of patients with breast cancer (BC). The aim of the present study is to provide an up-to-date overview of immediate breast reconstruction (IBR) in hospitals in the Netherlands over the past 10 years. PATIENTS AND
methodsNationwide data of patients with BC who underwent a mastectomy for ductal carcinoma in situ (DCIS) or invasive BC between January 2012 and September 2022 were requested from the Dutch Breast Cancer Audit (NBCA). Primary outcome was the incidence and trend in application of IBR. Secondary outcomes were factors associated with the use of IBR and the variation among Dutch hospitals.
resultsIn total, 56,164 patients underwent a mastectomy for DCIS (n = 8334) or invasive BC (n = 47,830) (2012-2022). The use of IBR for DCIS increased from 39 in 2012 to 48% in 2022 (2012-2017; range 0-85% and 2018-2021; range 0-83%). For DCIS, age < 50 years and lower DCIS grade were positively associated with IBR. The use of IBR for invasive BC increased from 16 in 2012 to 29% in 2022 (2012-2017; range 0-74%, 2018-2022; range 0-77%). For invasive BC, age < 40 years, neoadjuvant chemotherapy, and no adjuvant radiotherapy were positively associated with IBR.
conclusionDespite an overall increase of IBR, national variations remain. Further prospective research is initiated ( www.decidestudie.com ) to investigate this variation, which may lead to a more even distribution of IBR use among hospitals in the Netherlands.
Indexed as
Identifiers
39560828What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.